GlassScriptPhysician profile
Chadrick Leon Hull
NPI 1548599608
$3,980.67
in general payments reported to CMS, 2019-2025
32 companies · $752 in 2025
The $752 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $805 · 2023: $851 · 2024: $824 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $866.52 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $498.13 | 2021-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.04 | 2021-2025 | Xifaxan |
| Abbvie INC. | $335.66 | 2021-2025 | |
| Corcept Therapeutics | $241.80 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $230.50 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $212.38 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $177.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $174.72 | 2021-2025 | Trintellix |
| Amgen INC. | $142.93 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Abbott Laboratories | $104.59 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $87.87 | 2024-2025 | Auvelity |
| Dexcom, INC. | $55.47 | 2023-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $55.06 | 2024-2025 | Voquezna |
| Pfizer INC. | $46.25 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $39.56 | 2023-2024 | Senza |
| Paratek Pharmaceuticals, INC. | $38.87 | 2022-2024 | Nuzyra |
| Eisai INC. | $33.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.66 | 2021-2022 | |
| Antares Pharma, INC. | $29.25 | 2024-2025 | Xyosted |
| Inspire Medical Systems, INC. | $27.06 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $26.65 | 2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $25.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.69 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $22.85 | 2022 | |
| Genentech USA, INC. | $19.47 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $17.10 | 2023 | |
| Scilex Pharmaceuticals INC. | $15.26 | 2022 | |
| Tolmar, INC. | $14.86 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.58 | 2022 | |
| Amarin Pharma, INC. | $14.47 | 2021 | |
| Irhythm Technologies, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadrick Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.